

Richter completed the acquisition of Mediplus N.V.

Budapest, 22 October 2015 - Gedeon Richter Plc. ("Richter") announces today that it has completed the acquisition of Mediplus N.V. ("Mediplus") by purchasing the outstanding stake of the company. Mediplus is a marketing company based in Curaçao, which covers through its subsidiaries a number of countries in the Latin American region, namely: Ecuador, Peru, Chile and Bolivia. An initial 51% majority stake was acquired in May 2014. Subsequent to the present acquisition, Richter holds now 100% of Mediplus.

This step underlines the strategic aim towards the diversification of Richter's geographic presence in Latin America, one of the regions with fastest growing pharmaceutical markets worldwide.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (US\$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (US\$ 2.5 billion) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

Investors: Katalin Ördög
Media: Zsuzsa Beke

+36 1 431 5680
+36 1 431 4888